Eckert & Ziegler stock reports flat H1 revenue as EBIT falls

Published on 10/04/2026 at 22:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock was last at EUR 12.35 on October 2, 2026, while H1 adjusted EBIT fell 6 percent. Guidance stays at EUR 320 million in sales and EUR 80 million EBIT.

Bauhaus-Designposter mit geometrischen Formen, Primärfarben und MEDTECH-Schriftzug — Eckert & Ziegler DE0005659700 Medizintechnik: Bauhaus-Poster mit geometrischen Grundfarben und Atomstruktur-Motiv sowie MEDTECH-Sektor-Schriftzug, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) was last at EUR 12.35 on Xetra on October 2, 2026 at 5:37 p.m. CEST, up 0.16 percent from the prior close. The latest company picture combines flat first-half revenue with a lower adjusted operating result, according to Quartr on September 25, 2026.

H1 revenue holds at EUR 149.3 million

Revenue for the first half of 2026 stood at EUR 149.3 million, unchanged from the prior-year period, while adjusted EBIT declined 6 percent to EUR 33.3 million, Quartr reported.

The contrast between sales and earnings is the central operating issue. The Medical segment generated 7 percent EBIT growth, but Isotope Products posted a 24 percent EBIT decline, creating a clear split between the two businesses.

Medical growth offsets isotope pressure

Eckert & Ziegler operates through Medical and Isotope Products, supplying isotope technology components and radiopharmaceutical equipment for medical, scientific and industrial applications, according to the company's investor-relations page.

Management kept its 2026 targets unchanged at EUR 320 million of group sales and EUR 80 million of adjusted EBIT, both representing 3 percent growth in the figures summarized by Quartr. The guidance requires a stronger second half after EUR 33.3 million of adjusted EBIT in the first six months.

Cash flow from operations fell 42 percent to EUR 12.8 million in H1 2026, while the equity ratio strengthened to 57 percent, according to Quartr. That combination gives the balance sheet more weight in the investment case because operating earnings weakened while financial resilience improved.

Consensus target remains above EUR 21

On October 4, 2026, Investing.com listed a Strong Buy consensus from 3 analysts, with an average 12-month price target of EUR 21.600, a high of EUR 23.00 and a low of EUR 20.30. The average target lies 74.9 percent above the Xetra price of EUR 12.35.

The market is therefore weighing a wide gap between current execution and forward expectations. For the consensus to remain credible, the Medical segment's growth must offset the 24 percent EBIT decline in Isotope Products while the company delivers its second-half plan.

Investing.com lists November 12, 2026 as the next earnings date for the Q3 2026 report. That report will provide the next quantified test of the EUR 320 million sales and EUR 80 million adjusted EBIT targets.

Stock remains below its yearly high

Eckert & Ziegler stock had a 52-week range of EUR 12.01 to EUR 18.26 on October 2, 2026, with market capitalization of EUR 772.8 million and volume of 90,053 shares. The last price was 32.4 percent below the 52-week high.